Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to $28.3 million.

  • Pliant Therapeutics' Operating Expenses fell 5441.51% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.1 million, marking a year-over-year decrease of 1619.49%. This contributed to the annual value of $228.4 million for FY2024, which is 2295.87% up from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Operating Expenses is $28.3 million, which was down 5441.51% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Operating Expenses registered a high of $62.0 million during Q3 2024, and its lowest value of $24.7 million during Q2 2021.
  • Its 5-year average for Operating Expenses is $41.5 million, with a median of $43.4 million in 2023.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 4799.98% in 2022, then tumbled by 5441.51% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Operating Expenses stood at $26.6 million in 2021, then soared by 48.0% to $39.4 million in 2022, then grew by 19.49% to $47.0 million in 2023, then rose by 13.36% to $53.3 million in 2024, then plummeted by 46.98% to $28.3 million in 2025.
  • Its last three reported values are $28.3 million in Q3 2025, $45.6 million for Q2 2025, and $58.9 million during Q1 2025.